Spex Capital
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Spex Capital.
Key people at Spex Capital.
Key people at Spex Capital.
Spex Capital is a London-based investment management firm specializing in early-stage digital health and med-tech ventures, aiming to deliver global breakthroughs in healthcare systems. Their mission is to bridge the funding gap—often called the "valley of death"—for promising startups by providing capital, expertise, and strategic support to help these companies commercialize and scale, particularly within healthcare delivery systems like the NHS and beyond. They focus on disruptive technologies that align with sustainable development goals and impact investing standards, targeting investments primarily at seed to Series A stages with tickets ranging from £500k to £5m[1][2][3][4].
Founded in 2021 by Claudio D’Angelo, Spex Capital leverages deep sector expertise and a global network of partners including accelerators, universities, healthcare systems, and trade bodies. Their flagship vehicle, the Spex Venture Health-Tech Fund, is a €100 million fund designed to identify and support early-stage digital health startups worldwide. The firm’s evolution centers on a rigorous due diligence process and a commitment to impact-driven metrics aligned with UN Sustainable Development Goals, reflecting a strategic focus on digital health innovation and healthcare system transformation[1][2][4][5].
Spex Capital rides the accelerating trend of digital transformation in healthcare, a sector experiencing rapid growth driven by technological advances and increased demand for efficient, patient-centered care. The COVID-19 pandemic catalyzed adoption of digital health solutions, creating favorable market conditions with an estimated 28.5% CAGR in digital healthcare through 2026. By focusing on early-stage ventures, Spex Capital helps bridge the critical funding gap that often stalls innovation before it reaches commercialization, thus playing a pivotal role in shaping the future of healthcare delivery globally[4].
Looking ahead, Spex Capital is positioned to expand its influence by continuing to fund and scale transformative digital health startups that address systemic healthcare challenges. The firm’s commitment to impact metrics and strategic partnerships suggests it will remain a key player in driving sustainable innovation in healthcare. As digital health markets grow and healthcare systems worldwide seek scalable, tech-enabled solutions, Spex Capital’s role as a bridge investor and ecosystem connector will likely deepen, potentially expanding into new geographies and adjacent health-tech verticals[2][4].
In summary, Spex Capital combines focused expertise, a robust global network, and an impact-driven investment philosophy to accelerate early-stage digital health ventures, addressing critical gaps in healthcare innovation and funding.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 1, 2022 | Sano Genetics | $11.0M Series A | — | MMC Ventures, Redalpine Venture Partners, Spark Capital, Episode 1 Ventures |
